CDK 12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS 1‐ErbB‐ PI 3K signaling
- 30 August 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Reports
- Vol. 20 (10), e48058
- https://doi.org/10.15252/embr.201948058
Abstract
Cyclin‐dependent kinase 12 (CDK12) has emerged as an effective therapeutic target due to its ability to regulate DNA damage repair in human cancers, but little is known about the role of CDK12 in driving tumorigenesis. Here, we demonstrate that CDK12 promotes tumor initiation as a novel regulator of cancer stem cells (CSCs) and induces anti‐HER2 therapy resistance in human breast cancer. High CDK12 expression caused by concurrent amplification of CDK12 and HER2 in breast cancer patients is associated with disease recurrence and poor survival. CDK12 induces self‐renewal of breast CSCs and in vivo tumor‐initiating ability, and also reduces susceptibility to trastuzumab. Furthermore, CDK12 kinase activity inhibition facilitates anticancer efficacy of trastuzumab in HER2+ tumors, and mice bearing trastuzumab‐resistant HER2+ tumor show sensitivity to an inhibitor of CDK12. Mechanistically, the catalytic activity of CDK12 is required for the expression of genes involved in the activation of ErbB‐PI3K‐AKT or WNT‐signaling cascades. These results suggest that CDK12 is a major oncogenic driver and an actionable target for HER2+ breast cancer to replace or augment current anti‐HER2 therapies.Keywords
Funding Information
- National Research Foundation of Korea (2019R1A2C3006305)
This publication has 60 references indexed in Scilit:
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapyBreast Cancer Research and Treatment, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genesGenes & Development, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1Genes & Development, 2010
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiationNature Biotechnology, 2010
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasionOncogene, 2008
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005